VBI Vaccines Inc (NASDAQ:VBIV)’s share price reached a new 52-week low during trading on Friday . The company traded as low as $1.55 and last traded at $1.59, with a volume of 800 shares. The stock had previously closed at $1.59.
A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Thursday, November 22nd. ValuEngine raised shares of VBI Vaccines from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $8.63.
The company has a debt-to-equity ratio of 0.15, a current ratio of 1.61 and a quick ratio of 1.55.
A number of hedge funds have recently added to or reduced their stakes in VBIV. General American Investors Co. Inc. grew its stake in VBI Vaccines by 44.1% in the 2nd quarter. General American Investors Co. Inc. now owns 864,464 shares of the biopharmaceutical company’s stock worth $2,377,000 after buying an additional 264,464 shares in the last quarter. LMR Partners LLP bought a new stake in shares of VBI Vaccines in the 2nd quarter worth approximately $233,000. Dimensional Fund Advisors LP bought a new stake in shares of VBI Vaccines in the 2nd quarter worth approximately $223,000. Altshuler Shaham Ltd lifted its holdings in shares of VBI Vaccines by 11.5% in the 2nd quarter. Altshuler Shaham Ltd now owns 891,442 shares of the biopharmaceutical company’s stock worth $2,452,000 after acquiring an additional 91,800 shares during the last quarter. Finally, DRW Securities LLC bought a new stake in shares of VBI Vaccines in the 2nd quarter worth approximately $126,000. 47.97% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/11/30/vbi-vaccines-vbiv-reaches-new-52-week-low-at-1-55.html.
About VBI Vaccines (NASDAQ:VBIV)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.
Featured Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.